Legal & General Group’s Capricor Therapeutics CAPR Stock Holding History

Legal & General Group’s Portfolio CAPR Stock Details CAPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$927K	Buy	38,513 +1,375	+4%	+$41.7K	﹤0.01%	2230
2026 Q1	$1.13M	Buy	37,138 +33,169	+836%	+$884K	﹤0.01%	2102
2025 Q4	$115K	Sell	3,969 -341	-8%	-$4.45K	﹤0.01%	2630
2025 Q3	$31.1K	Sell	4,310 -36,963	-90%	-$272K	﹤0.01%	2878
2025 Q2	$410K	Buy	41,273 +3,205	+8%	+$33.9K	﹤0.01%	2494
2025 Q1	$361K	Buy	38,068 +7,285	+24%	+$101K	﹤0.01%	2500
2024 Q4	$425K	Buy	30,783 +28,058	+1,030%	+$492K	﹤0.01%	2516
2024 Q3	$41.4K	Hold	2,725	–	–	﹤0.01%	2820
2024 Q2	$13K	Buy	+2,725	New	+$15.2K	﹤0.01%	3211

Other funds holding CAPR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BCM

Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Legal & General Group's CAPR Position: Q2 2026 in Review

Legal & General Group increased its Capricor Therapeutics (CAPR) stake by 3.7% in Q2 2026, buying an estimated $41.7K and bringing the position to 38,513 shares worth $927K. The position accounts for ﹤0.01% of the portfolio, ranked #2230.

Legal & General Group first reported a position in CAPR in Q2 2024 and has held it in 9 quarters since. The position peaked at $1.13M in Q1 2026. 169 funds tracked by Wall St. Rank hold CAPR as of Q2 2026.

Legal & General Group held 38,513 shares of Capricor Therapeutics worth $927K as of Q2 2026.
Legal & General Group bought 1,375 Capricor Therapeutics shares in Q2 2026, an estimated $41.7K.
Capricor Therapeutics made up ﹤0.01% of Legal & General Group's portfolio in Q2 2026, its #2230 holding.
Legal & General Group first reported a position in Capricor Therapeutics in Q2 2024 and has held it in 9 quarters since.
Legal & General Group's Capricor Therapeutics position peaked at $1.13M in Q1 2026.
169 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q2 2026.

Based on Legal & General Group's 13F filing for Q2 2026, filed 14 Aug 2026.